Pyrimidine-2,4,6-triones:: A new effective and selective class of matrix metalloproteinase inhibitors

被引:123
作者
Grams, F [1 ]
Brandstetter, H
D'Alò, S
Geppert, D
Krell, HW
Leinert, H
Livi, V
Menta, E
Oliva, A
Zimmermann, G
机构
[1] Hoffmann La Roche Ag, Preclin Res Pharma, Discovery Technol, CH-4070 Basel, Switzerland
[2] Max Planck Inst Biochem, D-82152 Martinsried, Germany
[3] Novuspharma SpA, Chem Res, I-20052 Monza, Italy
[4] Roche Diagnost GMBH, Biol Res, D-82377 Penzberg, Germany
[5] Roche Diagnost GMBH, Chem Res, D-68305 Mannheim, Germany
关键词
barbiturate; cancer; drug design; gelatinase; inhibitor; matrix metalloproteinase;
D O I
10.1515/BC.2001.159
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Matrix metalloproteinases (MMPs) are a family of zinc endopeptidases that have been implicated in various disease processes. Different classes of MMP inhibitors, including hydroxamic acids, phosphinic acids and thiols, have been previously described. Most of these mimic peptides and most likely bind in a similar way to the corresponding peptide substrates. Here we desccribe pyrimidine-triones as a completely new class of metalloprotease inhibitors. While the pyrimidine-trione template is used as the zinc-chelating moiety, the substituents have been optimized to yield inhibitors comparable in their inhibition efficiency of matrix metalloproteinases to hydroxamic acid derivatives such as batimastat. However, they are much more specific for a small subgroup of MMPs, namely the gelatinases (MMP-2 and MMP-9).
引用
收藏
页码:1277 / 1285
页数:9
相关论文
共 24 条
  • [1] STROMELYSIN-1 - 3-DIMENSIONAL STRUCTURE OF THE INHIBITED CATALYTIC DOMAIN AND OF THE C-TRUNCATED PROENZYME
    BECKER, JW
    MARCY, AI
    ROKOSZ, LL
    AXEL, MG
    BURBAUM, JJ
    FITZGERALD, PMD
    CAMERON, PM
    ESSER, CK
    HAGMANN, WK
    HERMES, JD
    SPRINGER, JP
    [J]. PROTEIN SCIENCE, 1995, 4 (10) : 1966 - 1976
  • [2] Recent advances in matrix metalloproteinase inhibitor research
    Beckett, RP
    Davidson, AH
    Drummond, AH
    Huxley, P
    Whittaker, M
    [J]. DRUG DISCOVERY TODAY, 1996, 1 (01) : 16 - 26
  • [3] BEELEY NRA, 1994, CURR OPIN THER PAT, V4, P7
  • [4] THE X-RAY CRYSTAL-STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN NEUTROPHIL COLLAGENASE INHIBITED BY A SUBSTRATE-ANALOG REVEALS THE ESSENTIALS FOR CATALYSIS AND SPECIFICITY
    BODE, W
    REINEMER, P
    HUBER, R
    KLEINE, T
    SCHNIERER, S
    TSCHESCHE, H
    [J]. EMBO JOURNAL, 1994, 13 (06) : 1263 - 1269
  • [5] STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN FIBROBLAST COLLAGENASE COMPLEXED WITH AN INHIBITOR
    BORKAKOTI, N
    WINKLER, FK
    WILLIAMS, DH
    DARCY, A
    BROADHURST, MJ
    BROWN, PA
    JOHNSON, WH
    MURRAY, EJ
    [J]. NATURE STRUCTURAL BIOLOGY, 1994, 1 (02): : 106 - 110
  • [6] BRANDSTETTER H, 2001, IN PRESS J BIOL CHEM
  • [7] MATRILYSIN-INHIBITOR COMPLEXES - COMMON THEMES AMONG METALLOPROTEASES
    BROWNER, MF
    SMITH, WW
    CASTELHANO, AL
    [J]. BIOCHEMISTRY, 1995, 34 (20) : 6602 - 6610
  • [8] CAMPION C, 1990, Patent No. 9005719
  • [9] Dhanaraj V, 1999, CROAT CHEM ACTA, V72, P575
  • [10] GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.0830m.x